Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 28

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 28
---
 negotiations with the prospective investors and with reference to the prevailing market price of our Common Shares,
recent trends in such price and other factors. It is possible that not all of the securities we are offering pursuant to this prospectus
supplement will be sold at the closing, in which case our net proceeds would be reduced. We expect that the sale of the securities will
be completed on or around the date indicated on the cover page of this prospectus supplement.

The Common Shares may not
be sold in Canada or to or for the benefit of a Canadian resident. By purchasing the securities offered pursuant to this prospectus supplement,
the purchaser undertakes not to sell such securities in Canada or to a person resident in Canada prior to the expiry of a period of four
months and one day from closing of this offering.

<div align='center'>LEGAL MATTERS</div>

The validity of the issuance
of our Common Shares offered hereby and certain other matters of Canadian law will be passed upon for us by Daniel N. Bloch. Certain matters
of U.S. federal securities law relating to this offering will be passed upon for us by Greenberg Traurig, P.A., Tel Aviv, Israel.

<div align='center'>EXPERTS</div>

The financial statements of
Clearmind Medicine Inc. as of October 31, 2024 and 2023 and for the years then ended, as included in this prospectus supplement, have
been audited by Brightman Almagor Zohar & Co., a firm in the Deloitte global network, an independent registered public accounting
firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given the firm’s
authority as experts in accounting and auditing.

The audit report covering
the October 31, 2024 consolidated financial statements contains an explanatory paragraph that states that the Company’s recurring
losses from operations and lack of sufficient resources raise substantial doubt about the entity’s ability to continue as a going
concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.

Such financial statements
are incorporated in this prospectus supplement by reference in reliance upon such report given on the authority of said firm as experts
in auditing and accounting.

<div align='center'>S-15

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>

The SEC allows us to “incorporate
by reference” the information we file with it, which means that we can disclose